ocrelizumab and hyaluronidase

CHEBI:CHEBI_748689

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

pharm_class
Humanized [CS]
product_type
HUMAN PRESCRIPTION DRUG
listing_expiration_date
20251231
marketing_start_date
20240913
package_marketing_start_date
20240913
dosage_form
INJECTION, SOLUTION
route
SUBCUTANEOUS
marketing_category
BLA
nui
M0556300
pharm_class_cs
Antibodies, Monoclonal, Humanized [CS]
labeler_name
Genentech, Inc.
manufacturer_name
Genentech, Inc.
active_ingredient_name
OCRELIZUMAB
unii
A10SJL62JY
pharm_class_epc
CD20-directed Cytolytic Antibody [EPC]
pharm_class_moa
CD20-directed Antibody Interactions [MoA]
generic_name
ocrelizumab and hyaluronidase
brand_name
Ocrevus Zunovo
brand_name_base
Ocrevus Zunovo
product_ndc
50242-554
application_number
BLA761371
spl_id
f99d2e13-012f-4341-9f12-ed173ae6139f
active_ingredient_strength
920 mg/23mL
package_ndc
50242-554-86
package_description
1 VIAL, SINGLE-USE in 1 CARTON (50242-554-86) / 23 mL in 1 VIAL, SINGLE-USE
rxcui
2693465
spl_set_id
b216af61-99d0-42a3-afc2-b5bf86df1ec0
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class